Naxitamab

那西妥单抗

Report date: 2026/05/02 20:00:18

Base Information

Drug NameNaxitamab
Drug Alias Name那昔妥单抗Humanised 3F8Humanised anti-GD2 3F8 monoclonal antibodyNaxitamab-gqgkDanyelza +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionDisialoganglioside GD2 inhibitors
TargetsDisialoganglioside GD2
Therapy Area/IndicationsUveal melanomaSkin MelanomaCNS Embryonal Tumor +[11] 
Global Approved IndicationsNeuroblastoma
Approved Indications in ChinaNeuroblastoma
Original Approved Country/TerritoryUnited States
Original Approved Date2020/11/25
Country/TerritoryMainland China(BOAO LECHENG)CanadaUnited States +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesY-Mabs Therapeutics IncAdium Pharma SAMemorial Sloan Kettering Cancer Center +[9] 
Inactive CompaniesY-Mabs Inc
Active IndicationsNeuroblastomaSarcoma, EwingOsteosarcoma
Inactive IndicationsUveal melanomaSkin MelanomaCNS Embryonal Tumor +[8] 

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG